MorphoSys AG has increased its financial guidance for 2017 in the wake of a licensing deal with I-Mab Biopharma, a biologics company based in Shanghai, China. The agreement gives I-Mab the right to develop the German company’s antibody for multiple myeloma for the Chinese market.
